ArticleEndocrine-related cancer2026
Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-state transitions and microenvironmental remodeling in thyroid cancer progression revealed by single-cell and spatial transcriptomics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer exhibits pronounced cellular heterogeneity, yet the mechanisms underlying epithelial-mesenchymal transition (EMT) and tumor microenvironment (TME) remodeling remain incompletely understood. In this study, single-cell RNA sequencing of 92,849 cells from 20 thyroid tissue samples derived from underage and adult patients was performed to systematically characterize immune and epithelial heterogeneity through cell type annotation, subclustering, and functional enrichment analyses. A total of 26 distinct cell clusters were identified, encompassing immune and stromal compartments, with notable age- and stage-specific differences in T cell, epithelial, and macrophage subsets. EMT-high tumors were characterized by stromal enrichment, immune suppression, and transcriptional activation of canonical EMT drivers, including TGFB1, SNAI1/2, TWIST1/2, and ZEB1/2. Functional validation demonstrated that shRNA-mediated knockdown of PHTF2 or SNAI1 in TPC-1 and KTC-1 cell lines significantly inhibited proliferation and clonogenic capacity, accompanied by upregulation of CDH1 and downregulation of multiple EMT-associated genes. Furthermore, EMT-high tumors exhibited distinct drug sensitivity profiles, including reduced responsiveness to conventional chemotherapeutics and increased sensitivity to agents such as camptothecin and dabrafenib. Collectively, these findings identify PHTF2 and SNAI1 as key regulators of EMT and tumor cell proliferation in thyroid cancer, and suggest that EMT-driven TME remodeling contributes to immune evasion and therapeutic resistance, thereby revealing EMT-associated vulnerabilities as potential targets for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.